A specific binding member that binds human ED-B, wherein the specific binding member is labelled with an isotope selected from the group consisting of 76Br, 77Br, 123I, 124I, 131I and 211At and comprises an antigen-binding site that comprises an antibody VH domain and an antibody VL domain, wherein the antibody VH domain is selected from the group consisting of the L19 VH domain, and a VH domain comprising a VH CDR1, a VH CDR2 and a VH CDR3, wherein the VH CDR3 is the L19 VH CDR3 of SEQ ID NO. 3, the VH CDR1 is optionally L19 VH CDR1 of SEQ ID NO. 1, and the VH CDR2 is optionally L19 VH CDR2 of SEQ ID NO. 2; and wherein the antibody VL domain is optionally selected from the group consisting of the L19 VL domain, and a VL domain comprising a VL CDR1, a VL CDR2 and a VL CDR3, wherein the VL CDR3 is the L19 VL CDR3 of SEQ ID NO. 6, the VL CDR1 is optionally L19 VL CDR1 of SEQ ID NO. 4, and the VL CDR2 is optionally L19 VL CDR2 of SEQ ID NO. 5; the L19 VH domain and L19 VL domain sequences being disclosed in Pini et al. (1998) J. Biol. Chem. 273: 21769-21776; wherein the specific binding member comprises a mini-immunoglobulin comprising said antibody VH domain and antibody VL domain fused to epsilon S2-CH4 and dimerized or comprises a whole IgG1 antibody molecule; also methods and uses employing such a specific binding member. IMAGE IMAGE IMAGE IMAGE
展开▼
机译：结合人ED-B的特异性结合成员，其中所述特异性结合成员用选自以下的同位素标记：76 Br，77 Br，123 I，124 I，131 I和<211>在且包含抗原结合位点，该抗原结合位点包含抗体VH结构域和抗体VL结构域，其中抗体VH结构域选自L19 VH结构域和包含VH CDR1的VH结构域，VH CDR2和VH CDR3，其中VH CDR3是SEQ ID NO.1的L19 VH CDR3。如图3所示，VH CDR1任选地是SEQ ID NO.1的L19 VH CDR1。 VH CDR2任选地为SEQ ID NO.1的L19 VH CDR2。 2;其中抗体VL结构域任选地选自L19 VL结构域和包含VL CDR1，VL CDR2和VL CDR3的VL结构域，其中VL CDR3是SEQ ID NO.1的L19 VL CDR3。在图6中，VL CDR1任选地是SEQ ID NO.1的L19 VL CDR1。 VL CDR2任选地为SEQ ID NO.4的L19 VL CDR2。 5; Pini等人公开了L19 VH结构域和L19 VL结构域序列。 （1998）生物化学杂志。化学273：21769-21776;其中所述特异性结合成员包含微型免疫球蛋白，所述微型免疫球蛋白包含所述抗体VH结构域和抗体VL结构域，所述抗体VH结构域和抗体VL结构域与εS2-CH4融合并二聚或包含完整的IgG1抗体分子;还涉及采用这种特异性结合成员的方法和用途。 <图像> <图像> <图像> <图像>
展开▼
